Amneal Pharmaceuticals, Inc. (AMRX) announced Wednesday it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $3.82, but opened at $3.94. Amneal Pharmaceuticals shares last traded at $3.83, with a volume of 94,523 shares. Analyst Upgrades and Downgrades AMRX has been the subject of a number of research […]
StockNews.com initiated coverage on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a research note published on Wednesday. The firm issued a buy rating on the stock. Other research analysts have also issued reports about the stock. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $4.00 to $5.00 and gave the […]
Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) and American Green (OTCMKTS:ERBB – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation. Insider and Institutional Ownership 31.7% of Amneal Pharmaceuticals […]